Literature DB >> 22485082

Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response.

.   

Abstract

Year:  2012        PMID: 22485082      PMCID: PMC3317512     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  17 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

3.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.

Authors:  Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Østergaard Thomsen; Mark Andrew Ainsworth
Journal:  Scand J Gastroenterol       Date:  2010-11-18       Impact factor: 2.423

6.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

7.  Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.

Authors:  Sophie Candon; Alexis Mosca; Frank Ruemmele; Olivier Goulet; Lucienne Chatenoud; Jean-Pierre Cézard
Journal:  Clin Immunol       Date:  2005-08-25       Impact factor: 3.969

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 9.  Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.

Authors:  Klaus Bendtzen; Mark Ainsworth; Casper Steenholdt; Ole Østergaard Thomsen; Jørn Brynskov
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

10.  Infliximab pharmacokinetics in inflammatory bowel disease patients.

Authors:  David Ternant; Alexandre Aubourg; Charlotte Magdelaine-Beuzelin; Danielle Degenne; Hervé Watier; Laurence Picon; Gilles Paintaud
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681

View more
  3 in total

Review 1.  The Prospects of an Active Vaccine Against Asthma Targeting IL-5.

Authors:  Martin F Bachmann; Aadil El-Turabi; Antonia Fettelschoss-Gabriel; Monique Vogel
Journal:  Front Microbiol       Date:  2018-10-24       Impact factor: 5.640

2.  Interleukin 31 in insect bite hypersensitivity-Alleviating clinical symptoms by active vaccination against itch.

Authors:  Florian Olomski; Victoria Fettelschoss; Sigridur Jonsdottir; Katharina Birkmann; Franziska Thoms; Eliane Marti; Martin F Bachmann; Thomas M Kündig; Antonia Fettelschoss-Gabriel
Journal:  Allergy       Date:  2020-02-06       Impact factor: 13.146

3.  Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease.

Authors:  Aswani Thurlapati; Siva Santosh Kumar Gandu; Shreedhar Kulkarni
Journal:  Cureus       Date:  2021-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.